The potential role for recombinant factor VIIa in cardiac surgery

Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 77–AIC 79 Leave a comment
Click any image to enlarge
Authors:

Recombinant factor VIIa (rFVIIa, Novoseven®, Novo
Nordisk®, Denmark) is established for the management
of bleeding episodes in haemophiliac patients with inhibitors.
Interest has been growing in the use of this drug
for the management of severe intractable bleeding following
major trauma and surgery.








Advertisement

For UK healthcare professionals only


THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT